Selected research
Industry Research
Monoclonal Antibody Biologics and Biosimilars Industry Research Report 2026
Market perspective
The global Monoclonal Antibody Biologics and Biosimilars market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Monoclonal Antibody Biologics and Biosimilars market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Monoclonal Antibody Biologics and Biosimilars market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Monoclonal Antibody Biologics and Biosimilars market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Monoclonal Antibody Biologics and Biosimilars include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Biogen and Amgen, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Monoclonal Antibody Biologics and Biosimilars market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Monoclonal Antibody Biologics and Biosimilars.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Monoclonal Antibody Biologics and Biosimilars Market by Company
Sanofi
Johnson & Johnson
Novartis
Merck
Roche
Eli Lilly
Pfizer
Biogen
Amgen
AbbVie
Sobi
Innovent Biologics
Celltrion
3SBIO
Monoclonal Antibody Biologics and Biosimilars Segment by Type
Biologics
Biosimilars
Monoclonal Antibody Biologics and Biosimilars Segment by Application
Cancer
Autoimmune Disease
Other
Monoclonal Antibody Biologics and Biosimilars Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibody Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibody Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibody Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Monoclonal Antibody Biologics and Biosimilars companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Biologics
- Biosimilars
Applications
- Cancer
- Autoimmune Disease
- Other
Companies covered
- Sanofi
- Johnson & Johnson
- Novartis
- Merck
- Roche
- Eli Lilly
- Pfizer
- Biogen
- Amgen
- AbbVie
- Sobi
- Innovent Biologics
- Celltrion
- 3SBIO
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Monoclonal Antibody Biologics and Biosimilars by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Biologics
- 2.2.3 Biosimilars
- 2.3 Monoclonal Antibody Biologics and Biosimilars by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer
- 2.3.3 Autoimmune Disease
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Monoclonal Antibody Biologics and Biosimilars Breakdown Data by Type
- 3.1 Global Monoclonal Antibody Biologics and Biosimilars Historic Market Size by Type (2021-2026)
- 3.2 Global Monoclonal Antibody Biologics and Biosimilars Forecasted Market Size by Type (2027-2032)
4 Monoclonal Antibody Biologics and Biosimilars Breakdown Data by Application
- 4.1 Global Monoclonal Antibody Biologics and Biosimilars Historic Market Size by Application (2021-2026)
- 4.2 Global Monoclonal Antibody Biologics and Biosimilars Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Monoclonal Antibody Biologics and Biosimilars Market Perspective (2021-2032)
- 5.2 Global Monoclonal Antibody Biologics and Biosimilars Growth Trends by Region
- 5.2.1 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Monoclonal Antibody Biologics and Biosimilars Historic Market Size by Region (2021-2026)
- 5.2.3 Monoclonal Antibody Biologics and Biosimilars Forecasted Market Size by Region (2027-2032)
- 5.3 Monoclonal Antibody Biologics and Biosimilars Market Dynamics
- 5.3.1 Monoclonal Antibody Biologics and Biosimilars Industry Trends
- 5.3.2 Monoclonal Antibody Biologics and Biosimilars Market Drivers
- 5.3.3 Monoclonal Antibody Biologics and Biosimilars Market Challenges
- 5.3.4 Monoclonal Antibody Biologics and Biosimilars Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Monoclonal Antibody Biologics and Biosimilars Players by Revenue
- 6.1.1 Global Top Monoclonal Antibody Biologics and Biosimilars Players by Revenue (2021-2026)
- 6.1.2 Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Players (2021-2026)
- 6.2 Global Monoclonal Antibody Biologics and Biosimilars Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Monoclonal Antibody Biologics and Biosimilars Head Office and Area Served
- 6.4 Global Monoclonal Antibody Biologics and Biosimilars Players, Product Type & Application
- 6.5 Global Monoclonal Antibody Biologics and Biosimilars Manufacturers Established Date
- 6.6 Global Monoclonal Antibody Biologics and Biosimilars Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032)
- 7.2 North America Monoclonal Antibody Biologics and Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026)
- 7.4 North America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032)
- 8.2 Europe Monoclonal Antibody Biologics and Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026)
- 8.4 Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032)
- 9.2 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032)
- 10.2 South America Monoclonal Antibody Biologics and Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026)
- 10.4 South America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032)
- 11.2 Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi
- 12.1.1 Sanofi Company Information
- 12.1.2 Sanofi Business Overview
- 12.1.3 Sanofi Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2021-2026)
- 12.1.4 Sanofi Monoclonal Antibody Biologics and Biosimilars Product Portfolio
- 12.1.5 Sanofi Recent Developments
- 12.2 Johnson & Johnson
- 12.2.1 Johnson & Johnson Company Information
- 12.2.2 Johnson & Johnson Business Overview
- 12.2.3 Johnson & Johnson Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2021-2026)
- 12.2.4 Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Product Portfolio
- 12.2.5 Johnson & Johnson Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2021-2026)
- 12.3.4 Novartis Monoclonal Antibody Biologics and Biosimilars Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Merck
- 12.4.1 Merck Company Information
- 12.4.2 Merck Business Overview
- 12.4.3 Merck Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2021-2026)
- 12.4.4 Merck Monoclonal Antibody Biologics and Biosimilars Product Portfolio
- 12.4.5 Merck Recent Developments
- 12.5 Roche
- 12.5.1 Roche Company Information
- 12.5.2 Roche Business Overview
- 12.5.3 Roche Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2021-2026)
- 12.5.4 Roche Monoclonal Antibody Biologics and Biosimilars Product Portfolio
- 12.5.5 Roche Recent Developments
- 12.6 Eli Lilly
- 12.6.1 Eli Lilly Company Information
- 12.6.2 Eli Lilly Business Overview
- 12.6.3 Eli Lilly Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2021-2026)
- 12.6.4 Eli Lilly Monoclonal Antibody Biologics and Biosimilars Product Portfolio
- 12.6.5 Eli Lilly Recent Developments
- 12.7 Pfizer
- 12.7.1 Pfizer Company Information
- 12.7.2 Pfizer Business Overview
- 12.7.3 Pfizer Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2021-2026)
- 12.7.4 Pfizer Monoclonal Antibody Biologics and Biosimilars Product Portfolio
- 12.7.5 Pfizer Recent Developments
- 12.8 Biogen
- 12.8.1 Biogen Company Information
- 12.8.2 Biogen Business Overview
- 12.8.3 Biogen Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2021-2026)
- 12.8.4 Biogen Monoclonal Antibody Biologics and Biosimilars Product Portfolio
- 12.8.5 Biogen Recent Developments
- 12.9 Amgen
- 12.9.1 Amgen Company Information
- 12.9.2 Amgen Business Overview
- 12.9.3 Amgen Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2021-2026)
- 12.9.4 Amgen Monoclonal Antibody Biologics and Biosimilars Product Portfolio
- 12.9.5 Amgen Recent Developments
- 12.10 AbbVie
- 12.10.1 AbbVie Company Information
- 12.10.2 AbbVie Business Overview
- 12.10.3 AbbVie Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2021-2026)
- 12.10.4 AbbVie Monoclonal Antibody Biologics and Biosimilars Product Portfolio
- 12.10.5 AbbVie Recent Developments
- 12.11 Sobi
- 12.11.1 Sobi Company Information
- 12.11.2 Sobi Business Overview
- 12.11.3 Sobi Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2021-2026)
- 12.11.4 Sobi Monoclonal Antibody Biologics and Biosimilars Product Portfolio
- 12.11.5 Sobi Recent Developments
- 12.12 Innovent Biologics
- 12.12.1 Innovent Biologics Company Information
- 12.12.2 Innovent Biologics Business Overview
- 12.12.3 Innovent Biologics Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2021-2026)
- 12.12.4 Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Product Portfolio
- 12.12.5 Innovent Biologics Recent Developments
- 12.13 Celltrion
- 12.13.1 Celltrion Company Information
- 12.13.2 Celltrion Business Overview
- 12.13.3 Celltrion Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2021-2026)
- 12.13.4 Celltrion Monoclonal Antibody Biologics and Biosimilars Product Portfolio
- 12.13.5 Celltrion Recent Developments
- 12.14 3SBIO
- 12.14.1 3SBIO Company Information
- 12.14.2 3SBIO Business Overview
- 12.14.3 3SBIO Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2021-2026)
- 12.14.4 3SBIO Monoclonal Antibody Biologics and Biosimilars Product Portfolio
- 12.14.5 3SBIO Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst